<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;ff=20231115170746&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;ff=20231115170746&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 15 Nov 2023 22:07:48 +0000</lastbuilddate>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Swollen Right Upper Limb in a Man in His 60s Undergoing Hemodialysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966822/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4245. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966822/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966822</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4245>10.1001/jamacardio.2023.4245</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966822</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Shengmei Liu</dc:creator>
<dc:creator>Sixian Hu</dc:creator>
<dc:creator>Liqing Peng</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Swollen Right Upper Limb in a Man in His 60s Undergoing Hemodialysis</dc:title>
<dc:identifier>pmid:37966822</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4245</dc:identifier>
</item>
<item>
<title>Irregular Rhythm in a Middle-Aged Man Presenting With New-Onset Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4249. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966819</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4249>10.1001/jamacardio.2023.4249</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966819</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hussam Ali</dc:creator>
<dc:creator>Ilaria Passarelli</dc:creator>
<dc:creator>Riccardo Cappato</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Irregular Rhythm in a Middle-Aged Man Presenting With New-Onset Heart Failure</dc:title>
<dc:identifier>pmid:37966819</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4249</dc:identifier>
</item>
<item>
<title>Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4147. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the effect of tafamidis on cardiac function in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (≥50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (≤40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e') were compared in patients receiving tafamidis, 80 mg, vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49; P = .002; LV global longitudinal strain, -1.02%; 95% CI, -1.73 to -0.31; P = .005; septal E/e', -3.11; 95% CI, -5.50 to -0.72; P = .01; lateral E/e', -2.35; 95% CI, -4.01 to -0.69; P = .006).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01994889.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966817/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966817</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4147>10.1001/jamacardio.2023.4147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966817</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Nowell Fine</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:creator>Fabio Fernandes</dc:creator>
<dc:creator>Neil J Weissman</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Kurt Boman</dc:creator>
<dc:creator>Balarama Gundapaneni</dc:creator>
<dc:creator>Marla B Sultan</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37966817</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4147</dc:identifier>
</item>
<item>
<title>Myocardial infarction caused by in situ thrombosis of a patent foramen ovale assessed by optical coherence tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad753. doi: 10.1093/eurheartj/ehad753. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966576</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad753>10.1093/eurheartj/ehad753</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966576</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Wenhao Liu</dc:creator>
<dc:creator>Beibei Song</dc:creator>
<dc:creator>Bo Li</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial infarction caused by in situ thrombosis of a patent foramen ovale assessed by optical coherence tomography</dc:title>
<dc:identifier>pmid:37966576</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad753</dc:identifier>
</item>
<item>
<title>Multi-modality imaging diagnosing 'wandering non-coronary Valsalva sinus aneurysm'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966522/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad758. doi: 10.1093/eurheartj/ehad758. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966522/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966522</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad758>10.1093/eurheartj/ehad758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966522</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Boyu Kong</dc:creator>
<dc:creator>Xin Dong</dc:creator>
<dc:creator>Dianbo Cao</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multi-modality imaging diagnosing 'wandering non-coronary Valsalva sinus aneurysm'</dc:title>
<dc:identifier>pmid:37966522</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad758</dc:identifier>
</item>
<item>
<title>The cardiovascular effects of novel weight loss therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>The prevalence of overweight and obesity has reached pandemic proportions. Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke. The rising prevalence of obesity may counteract the recent advances in primary and secondary prevention of CV disease. Overweight and obesity are common in patients with CV disease; however, cardiologists face several challenges...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad664. doi: 10.1093/eurheartj/ehad664. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The prevalence of overweight and obesity has reached pandemic proportions. Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke. The rising prevalence of obesity may counteract the recent advances in primary and secondary prevention of CV disease. Overweight and obesity are common in patients with CV disease; however, cardiologists face several challenges in managing body weight in this population. Many may not consider obesity as a therapeutic target probably because there were no previous highly effective and safe pharmacologic interventions to consider. In addition, they may not have the expertise or resources to implement lifestyle interventions and may have limited familiarity with obesity pharmacotherapy. Moreover, the long-term CV effects of obesity pharmacotherapy remain uncertain due to limited CV outcome data with weight loss as the primary intervention. Although current CV guidelines recognize the importance of weight loss, they primarily focus on lifestyle modifications, with fewer details on strategies to utilize obesity pharmacotherapy and surgery. However, the recent 2022 American Diabetes Association/European Association for the Study of Diabetes consensus on the management of Type 2 diabetes has moved up weight management to the front of the treatment algorithm, by prioritizing the use of pharmacologic interventions such as glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, which have potent weight-lowering effects, in addition to glucose-lowering effects. This review appraises the current evidence regarding the CV effects of weight-loss interventions. Considering this evidence, practical guidance is provided to assist cardiologists in developing and implementing treatment plans, which may allow optimal weight management while maximizing CV benefits and minimizing side effects to improve the overall well-being of people with CV disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37966486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad664>10.1093/eurheartj/ehad664</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966486</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Melanie Davies</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Julio Rosenstock</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The cardiovascular effects of novel weight loss therapies</dc:title>
<dc:identifier>pmid:37966486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad664</dc:identifier>
</item>
<item>
<title>Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37965787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD^(+)-based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD^(+)-based therapy for heart failure. The data also show that NAD^(+)-based therapy can be useful in pre-existing heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Strategies to increase cellular NAD<sup>+</sup> (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD<sup>+</sup>-based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation of sirtuin, especially Sirt3 (sirtuin 3), and mitochondrial protein acetylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We induced cardiac dysfunction by pressure overload in SIRT3-deficient (knockout) mice and compared their response with nicotinamide riboside chloride treatment with wild-type mice. To model a therapeutic approach, we initiated the treatment in mice with established cardiac dysfunction and found nicotinamide riboside chloride improved mitochondrial function and blunted heart failure progression. Similar benefits were observed in wild-type and knockout mice. Boosting NAD<sup>+</sup> level improved the function of NAD(H) redox-sensitive SDR (short-chain dehydrogenase/reductase) family proteins. Upregulation of Mrpp2 (mitochondrial ribonuclease P protein 2), a multifunctional SDR protein and a subunit of mitochondrial ribonuclease P, improves mitochondrial DNA transcripts processing and electron transport chain function. Activation of SDRs in the retinol metabolism pathway stimulates RXRα (retinoid X receptor α)/PPARα (proliferator-activated receptor α) signaling and restores mitochondrial oxidative metabolism. Downregulation of Mrpp2 and impaired mitochondrial ribonuclease P were found in human failing hearts, suggesting a shared mechanism of defective mitochondrial biogenesis in mouse and human heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD<sup>+</sup>-based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD<sup>+</sup>-based therapy for heart failure. The data also show that NAD<sup>+</sup>-based therapy can be useful in pre-existing heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37965787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37965787</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066039>10.1161/CIRCULATIONAHA.123.066039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37965787</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Matthew A Walker</dc:creator>
<dc:creator>Hongye Chen</dc:creator>
<dc:creator>Aprajita Yadav</dc:creator>
<dc:creator>Julia Ritterhoff</dc:creator>
<dc:creator>Outi Villet</dc:creator>
<dc:creator>Tim McMillen</dc:creator>
<dc:creator>Yuliang Wang</dc:creator>
<dc:creator>Hayley Purcell</dc:creator>
<dc:creator>Danijel Djukovic</dc:creator>
<dc:creator>Daniel Raftery</dc:creator>
<dc:creator>Nina Isoherranen</dc:creator>
<dc:creator>Rong Tian</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation</dc:title>
<dc:identifier>pmid:37965787</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066039</dc:identifier>
</item>
<item>
<title>In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37965733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These findings show that in vivo AAV9-ABEmax editing can correct the variant Scn5a allele, effectively ameliorating arrhythmia phenotypes. Our results offer a proof of concept for the treatment of hereditary arrhythmias.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.065624. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pathogenic variants in <i>SCN5A</i> can result in long QT syndrome type 3, a life-threatening genetic disease. Adenine base editors can convert targeted A T base pairs to G C base pairs, offering a promising tool to correct pathogenic variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated a long QT syndrome type 3 mouse model by introducing the T1307M pathogenic variant into the <i>Scn5a</i> gene. The adenine base editor was split into 2 smaller parts and delivered into the heart by adeno-associated virus serotype 9 (AAV9-ABEmax) to correct the T1307M pathogenic variant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both homozygous and heterozygous T1307M mice showed significant QT prolongation. Carbachol administration induced torsades de pointes or ventricular tachycardia for homozygous T1307M mice (20%) but not for heterozygous or wild-type mice. A single intraperitoneal injection of AAV9-ABEmax at postnatal day 14 resulted in up to 99.20% <i>Scn5a</i> transcripts corrected in T1307M mice. <i>Scn5a</i> mRNA correction rate >;60% eliminated QT prolongation; <i>Scn5a</i> mRNA correction rate &lt;60% alleviated QT prolongation. Partial <i>Scn5a</i> correction resulted in cardiomyocyte heterogeneity, which did not induce severe arrhythmias. We did not detect off-target DNA or RNA editing events in ABEmax-treated mouse hearts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings show that in vivo AAV9-ABEmax editing can correct the variant <i>Scn5a</i> allele, effectively ameliorating arrhythmia phenotypes. Our results offer a proof of concept for the treatment of hereditary arrhythmias.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37965733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37965733</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065624>10.1161/CIRCULATIONAHA.123.065624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37965733</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Man Qi</dc:creator>
<dc:creator>Shuhong Ma</dc:creator>
<dc:creator>Jingtong Liu</dc:creator>
<dc:creator>Xujie Liu</dc:creator>
<dc:creator>Jingjing Wei</dc:creator>
<dc:creator>Wen-Jing Lu</dc:creator>
<dc:creator>Siyao Zhang</dc:creator>
<dc:creator>Yun Chang</dc:creator>
<dc:creator>Yongshuai Zhang</dc:creator>
<dc:creator>Kejia Zhong</dc:creator>
<dc:creator>Yuting Yan</dc:creator>
<dc:creator>Min Zhu</dc:creator>
<dc:creator>Yabing Song</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Guoliang Hao</dc:creator>
<dc:creator>Jianbing Wang</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Andrew S Lee</dc:creator>
<dc:creator>Xiangbo Chen</dc:creator>
<dc:creator>Yongming Wang</dc:creator>
<dc:creator>Feng Lan</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice</dc:title>
<dc:identifier>pmid:37965733</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065624</dc:identifier>
</item>
<item>
<title>Revealing the structure of the cardiac myosin filament</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37964080/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 14. doi: 10.1038/s41569-023-00960-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37964080/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37964080</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00960-5>10.1038/s41569-023-00960-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37964080</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Revealing the structure of the cardiac myosin filament</dc:title>
<dc:identifier>pmid:37964080</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00960-5</dc:identifier>
</item>
<item>
<title>Explaining how a cardiac reflex causes syncope</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37964079/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 14. doi: 10.1038/s41569-023-00961-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37964079/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37964079</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00961-4>10.1038/s41569-023-00961-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37964079</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Explaining how a cardiac reflex causes syncope</dc:title>
<dc:identifier>pmid:37964079</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00961-4</dc:identifier>
</item>
<item>
<title>Structural and signaling mechanisms of TAAR1 enabled preferential agonist design</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>Trace amine-associated receptor 1 (TAAR1) senses a spectrum of endogenous amine-containing metabolites (EAMs) to mediate diverse psychological functions and is useful for schizophrenia treatment without the side effects of catalepsy. Here, we systematically profiled the signaling properties of TAAR1 activation and present nine structures of TAAR1-Gs/Gq in complex with EAMs, clinical drugs, and synthetic compounds. These structures not only revealed the primary amine recognition pocket (PARP)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 9:S0092-8674(23)01131-5. doi: 10.1016/j.cell.2023.10.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Trace amine-associated receptor 1 (TAAR1) senses a spectrum of endogenous amine-containing metabolites (EAMs) to mediate diverse psychological functions and is useful for schizophrenia treatment without the side effects of catalepsy. Here, we systematically profiled the signaling properties of TAAR1 activation and present nine structures of TAAR1-Gs/Gq in complex with EAMs, clinical drugs, and synthetic compounds. These structures not only revealed the primary amine recognition pocket (PARP) harboring the conserved acidic D<sup>3.32</sup> for conserved amine recognition and "twin" toggle switch for receptor activation but also elucidated that targeting specific residues in the second binding pocket (SBP) allowed modulation of signaling preference. In addition to traditional drug-induced Gs signaling, Gq activation by EAM or synthetic compounds is beneficial to schizophrenia treatment. Our results provided a structural and signaling framework for molecular recognition by TAAR1, which afforded structural templates and signal clues for TAAR1-targeted candidate compounds design.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37963465</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.014>10.1016/j.cell.2023.10.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963465</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Pan Shang</dc:creator>
<dc:creator>Naikang Rong</dc:creator>
<dc:creator>Jing-Jing Jiang</dc:creator>
<dc:creator>Jie Cheng</dc:creator>
<dc:creator>Ming-Hui Zhang</dc:creator>
<dc:creator>Dongwei Kang</dc:creator>
<dc:creator>Lei Qi</dc:creator>
<dc:creator>Lulu Guo</dc:creator>
<dc:creator>Gong-Ming Yang</dc:creator>
<dc:creator>Qun Liu</dc:creator>
<dc:creator>Zhenzhen Zhou</dc:creator>
<dc:creator>Xiao-Bing Li</dc:creator>
<dc:creator>Kong-Kai Zhu</dc:creator>
<dc:creator>Qing-Biao Meng</dc:creator>
<dc:creator>Xiang Han</dc:creator>
<dc:creator>Wenqi Yan</dc:creator>
<dc:creator>Yalei Kong</dc:creator>
<dc:creator>Lejin Yang</dc:creator>
<dc:creator>Xiaohui Wang</dc:creator>
<dc:creator>Dapeng Lei</dc:creator>
<dc:creator>Xin Feng</dc:creator>
<dc:creator>Xinyong Liu</dc:creator>
<dc:creator>Xiao Yu</dc:creator>
<dc:creator>Yue Wang</dc:creator>
<dc:creator>Qian Li</dc:creator>
<dc:creator>Zhen-Hua Shao</dc:creator>
<dc:creator>Fan Yang</dc:creator>
<dc:creator>Jin-Peng Sun</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural and signaling mechanisms of TAAR1 enabled preferential agonist design</dc:title>
<dc:identifier>pmid:37963465</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.014</dc:identifier>
</item>
<item>
<title>Response by Sipilä and Kivimäki to Letter Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1509-1510. doi: 10.1161/CIRCULATIONAHA.123.066622. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37963202</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066622>10.1161/CIRCULATIONAHA.123.066622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963202</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Pyry N Sipilä</dc:creator>
<dc:creator>Mika Kivimäki</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Sipilä and Kivimäki to Letter Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</dc:title>
<dc:identifier>pmid:37963202</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066622</dc:identifier>
</item>
<item>
<title>Hot topics in valvular heart disease: tricuspid regurgitation, bicuspid aortic valve, artificial intelligence for aortic stenosis, and aortic aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37963104/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 14;44(43):4493-4496. doi: 10.1093/eurheartj/ehad743.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37963104/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37963104</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad743>10.1093/eurheartj/ehad743</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37963104</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in valvular heart disease: tricuspid regurgitation, bicuspid aortic valve, artificial intelligence for aortic stenosis, and aortic aneurysm</dc:title>
<dc:identifier>pmid:37963104</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad743</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37962872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 May 1;8(5):411. doi: 10.1001/jamacardio.2022.3436.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37962872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37962872</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2022.3436>10.1001/jamacardio.2022.3436</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37962872</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:37962872</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2022.3436</dc:identifier>
</item>
<item>
<title>Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.065600. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men in the EXPLORER-HCM study (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prespecified post hoc analysis of sex from the blinded, randomized EXPLORER-HCM trial of mavacamten versus placebo in symptomatic patients with obstructive HCM was performed. Baseline characteristics were compared with <i>t</i> tests for continuous variables (expressed as mean values) and χ<sup>2</sup> tests for categorical variables. Prespecified primary, secondary, and exploratory end points and echocardiographic measurements from baseline to end of treatment (week 30) were analyzed with ANCOVA for continuous end points and a generalized linear model with binomial distribution for binary end points, with adjustment for the baseline of each outcome, New York Heart Association class, β-blocker use, and ergometer type.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, women (n=102) were older (62 years versus 56 years; <i>P</i>&lt;0.0001), had lower peak oxygen consumption (16.7 mL·kg<sup>-1</sup>·min<sup>-1</sup> versus 21.3 mL·kg<sup>-1</sup>·min<sup>-1</sup>; <i>P</i>&lt;0.0001), were more likely to be assigned New York Heart Association class III (42% versus 17%; <i>P</i>&lt;0.0001), had worse health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 64 versus 75; <i>P</i>&lt;0.0001), and had higher baseline plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (1704 ng/L versus 990 ng/L; <i>P</i>=0.004) than men (n=149). After 30 weeks of mavacamten treatment, similar improvements were observed in women and men in the primary composite end point (percentage difference on mavacamten versus placebo, 22% versus 19%, respectively; <i>P</i>=0.759) and in the secondary end points of change in postexercise left ventricular outflow tract gradient (-42.4 mm Hg versus -33.6 mm Hg; <i>P</i>=0.348), change in peak oxygen consumption (1.2 mL·kg<sup>-1</sup>·min<sup>-1</sup> versus 1.6 mL·kg<sup>-1</sup>·min<sup>-1</sup>; <i>P</i>=0.633), and percentage achieving ≥1 New York Heart Association class improvement (41% versus 28%; <i>P</i>=0.254). However, women had greater improvement in health status (Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score 14.8 versus 6.1; <i>P</i>=0.026) and in the exploratory end point of NT-proBNP levels (-1322 ng/L versus -649 ng/L; <i>P</i>=0.0008).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03470545.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37961906</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065600>10.1161/CIRCULATIONAHA.123.065600</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961906</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sharon Cresci</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Sheila M Hegde</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Ester Kim Nilles</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</dc:title>
<dc:identifier>pmid:37961906</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065600</dc:identifier>
</item>
<item>
<title>Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. Therefore, activation of ERR could be a potential therapeutic intervention for HF. However, in vivo studies demonstrating the potential usefulness of ERR agonist for HF treatment are lacking, because compounds with pharmacokinetics appropriate for in vivo use have not been available.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a structure-based design approach, we designed and synthesized 2 structurally distinct pan-ERR agonists, SLU-PP-332 and SLU-PP-915. We investigated the effect of ERR agonist on cardiac function in a pressure overload-induced HF model in vivo. We conducted comprehensive functional, multi-omics (RNA sequencing and metabolomics studies), and genetic dependency studies both in vivo and in vitro to dissect the molecular mechanism, ERR isoform dependency, and target specificity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced HF without affecting cardiac hypertrophy. A broad spectrum of metabolic genes was transcriptionally activated by ERR agonists, particularly genes involved in fatty acid metabolism and mitochondrial function. Metabolomics analysis showed substantial normalization of metabolic profiles in fatty acid/lipid and tricarboxylic acid/oxidative phosphorylation metabolites in the mouse heart with 6-week pressure overload. ERR agonists increase mitochondria oxidative capacity and fatty acid use in vitro and in vivo. Using both in vitro and in vivo genetic dependency experiments, we show that ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection and definitively demonstrated target specificity. ERR agonism also led to downregulation of cell cycle and development pathways, which was partially mediated by E2F1 in cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961903/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37961903</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066542>10.1161/CIRCULATIONAHA.123.066542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961903</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Weiyi Xu</dc:creator>
<dc:creator>Cyrielle Billon</dc:creator>
<dc:creator>Hui Li</dc:creator>
<dc:creator>Andrea Wilderman</dc:creator>
<dc:creator>Lei Qi</dc:creator>
<dc:creator>Andrea Graves</dc:creator>
<dc:creator>Jernie Rae Dela Cruz Rideb</dc:creator>
<dc:creator>Yuanbiao Zhao</dc:creator>
<dc:creator>Matthew Hayes</dc:creator>
<dc:creator>Keyang Yu</dc:creator>
<dc:creator>McKenna Losby</dc:creator>
<dc:creator>Carissa S Hampton</dc:creator>
<dc:creator>Christiana M Adeyemi</dc:creator>
<dc:creator>Seok Jae Hong</dc:creator>
<dc:creator>Eleni Nasiotis</dc:creator>
<dc:creator>Chen Fu</dc:creator>
<dc:creator>Tae Gyu Oh</dc:creator>
<dc:creator>Weiwei Fan</dc:creator>
<dc:creator>Michael Downes</dc:creator>
<dc:creator>Ryan D Welch</dc:creator>
<dc:creator>Ronald M Evans</dc:creator>
<dc:creator>Aleksandar Milosavljevic</dc:creator>
<dc:creator>John K Walker</dc:creator>
<dc:creator>Brian C Jensen</dc:creator>
<dc:creator>Liming Pei</dc:creator>
<dc:creator>Thomas Burris</dc:creator>
<dc:creator>Lilei Zhang</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function</dc:title>
<dc:identifier>pmid:37961903</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066542</dc:identifier>
</item>
<item>
<title>Nitric Oxide Modulates Ca&lt;sup>;2+&lt;/sup>; Leak and Arrhythmias via S-Nitrosylation of CaMKII</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We conclude that prior S-nitrosylation of CaMKIIδ at cysteine-273 can limit subsequent β-adrenergic receptor-induced arrhythmias, but that S-nitrosylation at cysteine-290 might worsen or sustain β-adrenergic receptor-induced arrhythmias. This has important implications for the administration of NO donors in the clinical setting.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 14. doi: 10.1161/CIRCRESAHA.123.323571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Nitric oxide (NO) has been identified as a signaling molecule generated during β-adrenergic receptor stimulation in the heart. Furthermore, a role for NO in triggering spontaneous Ca<sup>2+</sup> release via <i>S</i>-nitrosylation of CaMKIIδ (Ca<sup>2+</sup>/calmodulin kinase II delta) is emerging. NO donors are routinely used clinically for their cardioprotective effects on the heart, but it is unknown how NO donors modulate the proarrhythmic CaMKII to alter cardiac arrhythmia incidence. We test the role of <i>S</i>-nitrosylation of CaMKIIδ at the Cysteine-273 inhibitory site and cysteine-290 activating site in cardiac Ca<sup>2+</sup> handling and arrhythmogenesis before and during β-adrenergic receptor stimulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured Ca<sup>2+</sup>-handling in isolated cardiomyocytes from C57BL/6J wild-type (WT) mice and mice lacking CaMKIIδ expression (CaMKIIδ-KO) or with deletion of the <i>S</i>-nitrosylation site on CaMKIIδ at cysteine-273 or cysteine-290 (CaMKIIδ-C273S and -C290A knock-in mice). Cardiomyocytes were exposed to NO donors, <i>S</i>-nitrosoglutathione (GSNO; 150 μM), sodium nitroprusside (200 μM), and β-adrenergic agonist isoproterenol (100 nmol/L).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both WT and CaMKIIδ-KO cardiomyocytes responded to isoproterenol with a full inotropic and lusitropic Ca<sup>2+</sup> transient response as well as increased Ca<sup>2+</sup> spark frequency. However, the increase in Ca<sup>2+</sup> spark frequency was significantly attenuated in CaMKIIδ-KO cardiomyocytes. The protection from isoproterenol-induced Ca<sup>2+</sup> sparks and waves was mimicked by GSNO pretreatment in WT cardiomyocytes but lost in CaMKIIδ-C273S cardiomyocytes. When GSNO was applied after isoproterenol, this protection was not observed in WT or CaMKIIδ-C273S but was apparent in CaMKIIδ-C290A. In Langendorff-perfused isolated hearts, GSNO pretreatment limited isoproterenol-induced arrhythmias in WT but not CaMKIIδ-C273S hearts, while GSNO exposure after isoproterenol sustained or exacerbated arrhythmic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We conclude that prior <i>S</i>-nitrosylation of CaMKIIδ at cysteine-273 can limit subsequent β-adrenergic receptor-induced arrhythmias, but that <i>S</i>-nitrosylation at cysteine-290 might worsen or sustain β-adrenergic receptor-induced arrhythmias. This has important implications for the administration of NO donors in the clinical setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37961889</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323571>10.1161/CIRCRESAHA.123.323571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961889</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Amelia S Power</dc:creator>
<dc:creator>Esther U Asamudo</dc:creator>
<dc:creator>Luke P I Worthington</dc:creator>
<dc:creator>Chidera C Alim</dc:creator>
<dc:creator>Raquel E Parackal</dc:creator>
<dc:creator>Rachel S Wallace</dc:creator>
<dc:creator>Obialunanma V Ebenebe</dc:creator>
<dc:creator>Joan Heller Brown</dc:creator>
<dc:creator>Mark J Kohr</dc:creator>
<dc:creator>Donald M Bers</dc:creator>
<dc:creator>Jeffrey R Erickson</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Nitric Oxide Modulates Ca&lt;sup>;2+&lt;/sup>; Leak and Arrhythmias via S-Nitrosylation of CaMKII</dc:title>
<dc:identifier>pmid:37961889</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323571</dc:identifier>
</item>
<item>
<title>Cooperative Response to Endocardial Notch Reveals Interaction With Hippo Pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Sequential Notch-dependent transcriptional regulation in the embryonic endocardium involves multiple factors. Notch activates certain noncoding elements through these factors and simultaneously suppresses elements that could hinder cardiac valve development and homeostasis. Biorxviv: https://www.biorxiv.org/content/10.1101/2023.03.23.533882v1.full.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 14. doi: 10.1161/CIRCRESAHA.123.323474. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The endocardium is a crucial signaling center for cardiac valve development and maturation. Genetic analysis has identified several human endocardial genes whose inactivation leads to bicuspid aortic valve formation and calcific aortic valve disease, but knowledge is very limited about the role played in valve development and disease by noncoding endocardial regulatory regions and upstream factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We manipulated Notch signaling in mouse embryonic endocardial cells by short-term and long-term coculture with OP9 stromal cells expressing Notch ligands and inhibition of Notch activity. We examined the transcriptional profile and chromatin accessibility landscape for each condition, integrated transcriptomic, transcription factor occupancy, chromatin accessibility, and proteomic datasets. We generated in vitro and in vivo models with CRISPR-Cas9-edited deletions of various noncoding regulatory elements and validated their regulatory potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified primary and secondary transcriptional responses to Notch ligands in the mouse embryonic endocardium, and a NOTCH-dependent transcriptional signature in valve development and disease. By defining the changes in the chromatin accessibility landscape and integrating with the landscape in developing mouse endocardium and adult human valves, we identify potential noncoding regulatory elements, validated selected candidates, propose interacting cofactors, and define the timeframe of their regulatory activity. Additionally, we found cooperative transcriptional repression with Hippo pathway by inhibiting nuclear Yap (Yes-associated protein) activity in the endocardium during cardiac valve development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sequential Notch-dependent transcriptional regulation in the embryonic endocardium involves multiple factors. Notch activates certain noncoding elements through these factors and simultaneously suppresses elements that could hinder cardiac valve development and homeostasis. Biorxviv: https://www.biorxiv.org/content/10.1101/2023.03.23.533882v1.full.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37961886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37961886</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323474>10.1161/CIRCRESAHA.123.323474</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37961886</guid>
<pubDate>Tue, 14 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Luis Luna-Zurita</dc:creator>
<dc:creator>Brenda Giselle Flores-Garza</dc:creator>
<dc:creator>Dimitrios Grivas</dc:creator>
<dc:creator>Marcos Siguero-Álvarez</dc:creator>
<dc:creator>José Luis de la Pompa</dc:creator>
<dc:date>2023-11-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cooperative Response to Endocardial Notch Reveals Interaction With Hippo Pathway</dc:title>
<dc:identifier>pmid:37961886</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323474</dc:identifier>
</item>
<item>
<title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 13. doi: 10.1038/s41569-023-00959-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37957335</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00959-y>10.1038/s41569-023-00959-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37957335</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</dc:title>
<dc:identifier>pmid:37957335</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00959-y</dc:identifier>
</item>
<item>
<title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 8:S0735-1097(23)07988-3. doi: 10.1016/j.jacc.2023.11.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the ISCHEMIA trial, the risk of ischemic events was similar in patients with stable coronary artery disease treated with an invasive (INV) strategy of angiography and percutaneous (PCI) or surgical (CABG) coronary revascularization and a conservative (CON) strategy of initial medical therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To analyze separately the outcomes of INV patients treated with PCI or CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients without preceding primary outcome events were categorized as INV-PCI or INV-CABG from the time of revascularization. The ISCHEMIA primary outcome (composite of cardiovascular death, protocol-defined myocardial infarction (MI) or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest) was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among INV-CABG patients, primary outcome events occurred in 84/512 (16.4%) at median follow-up of 2.85 years; 48 events (57.1%) occurred within 30 days after CABG, including 40 procedural MIs; among INV-PCI patients, primary outcome events occurred in 147/1500 (9.8%) at median follow-up of 2.94 years; 31 of which (21.1%) within 30 days after PCI, including 23 procedural MIs. In comparison, 352/2591 (13.6%) CON patients had primary outcome events at median follow-up 3.2 years, 22 of which (6.3%) within 30 days of randomization. The adjusted primary outcome risks (HR [95%CI]) were higher after both CABG and PCI within 30 days (16.25 (11.44-23.07) and 2.99 (1.97-4.53)) and lower thereafter (0.63 (0.44-0.89) and 0.66(0.53-0.82)).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37956961</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.002>10.1016/j.jacc.2023.11.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956961</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Eric R Bates</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Giuseppe Biondi-Zoccai</dc:creator>
<dc:creator>Tulio Caldonazo</dc:creator>
<dc:creator>Michael Farkouh</dc:creator>
<dc:creator>Mohamed Rahouma</dc:creator>
<dc:creator>John Puskas</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Mario Fl Gaudino</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:37956961</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.002</dc:identifier>
</item>
<item>
<title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231115170746&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 13:ehad770. doi: 10.1093/eurheartj/ehad770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: ECG abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD) but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study population was drawn from two prospective community-based SCD studies in Oregon, USA (2002-, discovery cohort) and California, USA (2015-, validation cohort). For this present sub-study, 231 discovery cases (2015-2017) and 203 validation cases (2015-2021) with ≥2 archived pre-SCD ECGs were ascertained, and were matched to 234 discovery and 203 validation controls based on age, sex, and duration between the ECGs. Dynamic ECG remodeling was measured as progression of a previously validated cumulative 6-variable ECG electrical risk score (ERS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Oregon SCD cases displayed greater ERS increase over time vs. controls [+1.06 (95% CI +0.89 to +1.24) vs. -0.05 (-0.21 to +0.11); p &lt; 0.001]. These findings were successfully replicated in California [+0.87 (+0.7 to +1.04) vs. -0.11 (-0.27 to 0.05); p &lt; 0.001]. In multivariable models, abnormal dynamic ECG remodeling improved SCD prediction over baseline ECG, demographics, and clinical SCD risk factors in both Oregon [AUC 0.770 (95% CI 0.727-0.812) increased to AUC 0.869 (95% CI 0.837-0.902)] and California cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231115170746&v=2.17.9.post6+86293ac">37956651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad770>10.1093/eurheartj/ehad770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956651</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>H N Pham</dc:creator>
<dc:creator>L Holmstrom</dc:creator>
<dc:creator>H Chugh</dc:creator>
<dc:creator>A Uy-Evanado</dc:creator>
<dc:creator>K Nakamura</dc:creator>
<dc:creator>Z Zhang</dc:creator>
<dc:creator>A Salvucci</dc:creator>
<dc:creator>J Jui</dc:creator>
<dc:creator>K Reinier</dc:creator>
<dc:creator>S S Chugh</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</dc:title>
<dc:identifier>pmid:37956651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad770</dc:identifier>
</item>





























</channel>
</rss>